Home » Stocks » EVOK

Evoke Pharma, Inc. (EVOK)

Stock Price: $1.14 USD -0.38 (-25.00%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $1.16 +0.02 (1.75%) May 13, 7:45 PM
Market Cap 49.21M
Revenue (ttm) 23,020
Net Income (ttm) -13.15M
Shares Out 25.49M
EPS (ttm) -0.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $1.14
Previous Close $1.52
Change ($) -0.38
Change (%) -25.00%
Day's Open 1.25
Day's Range 1.13 - 1.37
Day's Volume 1,815,961
52-Week Range 1.13 - 6.06

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOLANA BEACH, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today...

1 week ago - GlobeNewsWire

New patent expands intellectual property protection for nasal delivery of metoclopramide New patent expands intellectual property protection for nasal delivery of metoclopramide

1 month ago - GlobeNewsWire

SOLANA BEACH, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a commercial stage specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders ...

1 month ago - GlobeNewsWire

Among the health care stock movers Friday are ContraFect Corporation (NASDAQ: CFRX), Evoke Pharma, Inc. (NASDAQ: EVOK), Altimmune, Inc. (NASDAQ: ALT) and Novavax, Inc. (NASDAQ: NVAX). Here's why the sto...

Other stocks mentioned: ALT, CFRX, NVAX
2 months ago - Benzinga

Evoke Pharma, Inc. (EVOK) delivered earnings and revenue surprises of -125.00% and -98.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

SOLANA BEACH, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, tod...

2 months ago - GlobeNewsWire

SOLANA BEACH, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, anno...

3 months ago - GlobeNewsWire

SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, toda...

4 months ago - GlobeNewsWire

SOLANA BEACH, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, toda...

4 months ago - GlobeNewsWire

Healthcare practitioner survey indicates physicians' awareness and intent to prescribe newly-launched product Healthcare practitioner survey indicates physicians' awareness and intent to prescribe newly...

4 months ago - GlobeNewsWire

Investors need to pay close attention to Evoke Pharma (EVOK) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Gimoti™ commercial launch underway

6 months ago - GlobeNewsWire

Product launch provides healthcare providers a novel treatment approach for patients suffering from symptoms of acute and recurrent diabetic gastroparesis Product launch provides healthcare providers a ...

6 months ago - GlobeNewsWire

SOLANA BEACH, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced...

8 months ago - GlobeNewsWire

Gimoti commercial launch on track for the fourth quarter of 2020 Gimoti commercial launch on track for the fourth quarter of 2020

8 months ago - GlobeNewsWire

Preparing for commercial launch of GIMOTI™ in 4Q 2020 Preparing for commercial launch of GIMOTI™ in 4Q 2020

9 months ago - GlobeNewsWire

Preparing commercial launch of GIMOTI™ in 4Q 2020 Preparing commercial launch of GIMOTI™ in 4Q 2020

9 months ago - GlobeNewsWire

Preparing to initiate commercial sales of GIMOTI™ in 4Q 2020 Preparing to initiate commercial sales of GIMOTI™ in 4Q 2020

10 months ago - GlobeNewsWire

Cheap stocks are effectively Wall Street's casino.

Other stocks mentioned: AIM, IBIO, LIVX
10 months ago - Kiplinger

Evoke Pharma received a nod of approval from the U.S. Food and Drug Administration, and investors can now have confidence in EVOK stock.

10 months ago - InvestorPlace

Last Friday was my 56th consecutive green day of trading and I ended up ending it with a gross profit of $225,000, which easily blows past the $1 million mark for the streak and is several magnitudes be...

Other stocks mentioned: FRAN, NEON, SINT
10 months ago - Benzinga

In an update provided over the weekend, Evoke Pharma Inc. (NASDAQ: EVOK) said that the U.S.

10 months ago - 24/7 Wall Street

The binary event that was scheduled for last week panned out in favor of Evoke Pharma Inc (NASDAQ: EVOK).

10 months ago - Benzinga

Commercial Partner EVERSANA Prepares for GIMOTI Launch Evoke Extends Cash Runway into 2021

10 months ago - GlobeNewsWire

SOLANA BEACH, Calif., May 20, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced t...

11 months ago - GlobeNewsWire

Gimoti™ Prescription Drug User Fee Act (PDUFA) decision date set for June 19, 2020 Gimoti™ Prescription Drug User Fee Act (PDUFA) decision date set for June 19, 2020

1 year ago - GlobeNewsWire

SOLANA BEACH, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced ...

1 year ago - GlobeNewsWire

EVERSANA to commercialize and distribute Gimoti in the U.S.

1 year ago - GlobeNewsWire

The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.

1 year ago - Zacks Investment Research

PDUFA Target Goal Date is June 19, 2020 PDUFA Target Goal Date is June 19, 2020

1 year ago - GlobeNewsWire

SOLANA BEACH, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced ...

1 year ago - GlobeNewsWire

SOLANA BEACH, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced ...

1 year ago - GlobeNewsWire

SOLANA BEACH, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced ...

1 year ago - GlobeNewsWire

SOLANA BEACH, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced...

1 year ago - GlobeNewsWire

Evoke Pharma, Inc. (NASDAQ: EVOK) shares have lost about 51% of their value year to date compared to the 9.4%-gain in the iShares NASDAQ Biotechnology Index (NASDAQ: IBB) and a steeper 20% jump in the b...

1 year ago - Benzinga

During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.

2 years ago - Zacks Investment Research

About EVOK

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was inc... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Sep 25, 2013
CEO
David Gonyer
Employees
5
Stock Exchange
NASDAQ
Ticker Symbol
EVOK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Evoke Pharma stock is "Buy." The 12-month stock price forecast is 9.50, which is an increase of 733.33% from the latest price.

Price Target
$9.50
(733.33% upside)
Analyst Consensus: Buy